Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis
It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with multiple sclerosis
1 finding from 1 review
Relapse · people with multiple sclerosis
Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).
1 finding from 1 review
MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Proportion of participants who experienced operative or postoperative serious adverse events · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)
The intervention showed no clear difference in proportion of participants who experienced operative or… (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of participants who experienced improvement of composite functional endpoint over 12 months · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)
The intervention showed no clear difference in proportion of participants who experienced improvement of composite… (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of participants who experienced new relapses over 12 months · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)
The intervention showed no clear difference in proportion of participants who experienced new relapses over 12 months (moderate certainty).
1 finding from 1 review
Perinatal mortality · Women with a multiple pregnancy
Intramuscular (IM) progesterone showed no clear difference in perinatal death compared with no treatment or placebo (low certainty).
1 finding from 1 review
Low birthweight · Women with a multiple pregnancy
Vaginal progesterone showed no clear difference in infant birthweight less than 2500 g compared with no treatment or placebo (moderate certainty).
1 finding from 1 review
Preterm birth · Women with a multiple pregnancy
Vaginal progesterone showed no clear difference in preterm birth less than 37 weeks compared with no treatment or placebo (moderate certainty).
1 finding from 1 review
Preterm birth less than 28 weeks · Women with a multiple pregnancy
Vaginal progesterone showed no clear difference in preterm birth less than 28 weeks compared with no treatment or placebo (low certainty).
1 finding from 1 review
Preterm birth less than 34 weeks' gestation · Women with a multiple pregnancy
Intramuscular (IM) progesterone may leads to higher preterm birth less than 34 weeks compared with no treatment or placebo (low certainty).
1 finding from 1 review
Major neurodevelopmental disability at childhood · Women with a multiple pregnancy
1 finding from 1 review